Metrics to compare | CHM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCHMPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.4x | −5.3x | −0.5x | |
PEG Ratio | −0.01 | −0.05 | 0.00 | |
Price/Book | −2.5x | 1.8x | 2.6x | |
Price / LTM Sales | 0.8x | 15.4x | 3.2x | |
Upside (Analyst Target) | - | 150.0% | 47.8% | |
Fair Value Upside | Unlock | 14.6% | 6.7% | Unlock |
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurrent or progressive glioblastoma and membrane-bound matrix metalloproteinase-2 (MMP2) expressing solid tumors. It also develops CHM CORE-NK for the treatment of acute myeloid leukaemia/colorectal cancer, acute myeloid cancer, blood cancer, solid tumors, MMP2 expressing solid tumors, and CDH17 expressing solid tumors. The company was incorporated in 2020 and is based in Carlton, Australia.